Key result
Hyperinsulinemia linked to ~81% higher 24-month major cardiovascular events risk after drug-coated balloon PCI for ACS.
Why the study?
Few studies had explored the association between hyperinsulinemia and prognosis in ACS patients treated with drug-coated balloons.
Does baseline hyperinsulinemia increase the 24-month incidence of major adverse cardiovascular events in patients with acute coronary syndrome undergoing drug-coated balloon angioplasty?
Cohort (n=581)
No
Does baseline hyperinsulinemia increase the 24-month incidence of major adverse cardiovascular events in patients with acute coronary syndrome undergoing drug-coated balloon angioplasty?
Elevated baseline fasting insulin (>13.43 μIU/mL) is an independent predictor of 24-month MACE (primarily driven by non-fatal MI and target lesion revascularization) in ACS patients treated with paclitaxel drug-coated balloons.
Answers are grounded in this paper and cite their sources.
Hyperinsulinemia was associated with higher 24-month MACE risk after DCB PCI in ACS; hypothesis-generating, prospective trials needed before clinical adoption.
Background and Objectives : There were good clinical outcomes of drug-coated balloon (DCB) use in de-novo coronary lesions. However, few studies have explored the association between hyperinsulinemia and prognosis in patients treated with DCB. This study aimed to investigate the influence of hyperinsulinemia on major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS) who performed DCB procedure. Methods : 581patients with ACS and received DCB procedure were retrospectively enrolled. Patients were stratified into quartiles based on FINS measurements (Q1: ≤8.71 μIU/mL; Q2: 8.71–10.41 μIU/mL; Q3: 10.41-13.43 μIU/mL and Q4: >13.43 μIU/mL). Patients underwent clinical observation for a total of 24 months. The primary endpoint was MACE (all-cause death, non-fatal myocardial infarction, target lesion revascularization and target vessel revascularization) at 24 months. Results: 77 MACE occurred during the 24 months follow-up period, including 4 cases of cardiovascular death, 32 cases of Non-fatal MI, 36 cases of TLR and 5 cases of stroke. The highest quartile of FINS (Q4) had highest incidence of all cause MACE, non-fatal MI and TLR than other quartiles. There were no significant differences in cardiovascular death and stroke among four quartiles. Multivariate cox regression further identified hyperinsulinemia (HR1.808, 95% CI 1.020-3.208), diabetes (HR 2.345, 95% CI 1.323-4.156), age (HR 1.050, 95% CI 1.023–1.078), smoking (HR 1.645,95% CI 1.014-2.668) and diffused lesson (HR2.883, 95% CI 1.742-4.771) were independent factors of MACE (all P < 0.05). Conclusion: Hyperinsulinemia increased the incidence of MACE in patients performing PCI with DCB.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) conducted a cohort in Acute coronary syndrome treated with drug-coated balloon PCI (n=581). Hyperinsulinemia (highest fasting insulin quartile Q4: >13.43 μIU/mL) vs. Lower fasting insulin quartiles (Q1: ≤8.71 μIU/mL; Q2: 8.71–10.41 μIU/mL; Q3: 10.41–13.43 μIU/mL) was evaluated on Major adverse cardiovascular events (MACE: composite of all-cause mortality, non-fatal myocardial infarction, target lesion revascularization, and stroke) at 24 months (HR 1.808, 95% CI 1.020-3.208, p=0.043). Hyperinsulinemia independently increased the 24-month risk of major cardiovascular events in acute coronary syndrome patients treated with drug-coated balloon PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: